-
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
Lymphatic vessel hypoplasia in fetuses with Turner syndrome.
von Kaisenberg CS, Nicolaides KH, Brand-Saberi B.
Hum Reprod 1999;14:823-6. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation.
Snijders RJ, Sebire NJ, Nayar R, Souka A, Nicolaides KH.
Am J Med Genet 1999;86:205-7. -
Nuchal translucency as a marker of congenital heart disease.
Perdu M, Hyett JA, Sharland G, Snijders RS, Nicolaides KH.
Contracept Fertil Sex 1999;27:I-V. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
BMJ 1999;318:81-5.